Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel in refractory systemic lupus erythematosus or lupus nephritis
NL-OMON58828Phase 2Suspended
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rapcabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 arms), sponsored by Novartis. Primary endpoints: Complete renal response at Week 52, DORIS remission at Week 24 and 1 more. Started Sep 2025; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NL-OMON58828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58828.